AstraZeneca, following up on a layoff announcement last month, will make numerous cuts in R&D and eliminate a number of therapeutic treatments. The current round will result in a net loss of 1,800 R&D personnel; the company plans to cut 8,000 staffers overall by 2014, with 3,500 cuts coming from R&D. Major cuts include 550 employees in early-stage discovery at the Wilmington, DE site that identified Seroquel, 1,200 at its Charnwood, UK site and 900 at its research facility in Lund...